Brief: Cereno Scientific Receives FDA Clearance To Initiate Global Phase IIb Trial Of CS1 In Pulmonary Arterial Hypertension
08/12/2025 21:26
Dec 8 (Reuters) - Cereno Scientific AB CRNOSb.ST: CERENO SCIENTIFIC RECEIVES FDA CLEARANCE TO INITIATE GLOBAL PHASE IIB TRIAL OF CS1 IN PULMONARY ARTERIAL HYPERTENSION (PAH) Source text: ID:nWkr3Z81PS Further company coverage: [CRNOSb.ST] ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cereno Scientific AB
See all newsBrief: Cereno Scientific Expects Up To 15 Activated Sites By 2026 In Epimode Trial
Brief: Cereno Scientific Reports Positive Results From Study
Brief: Cereno Scientific Q2 Net Sales Sek 0
Sweden's Cereno Scientific Q2 net loss widens, hurt by clinical development costs
Brief: Cereno Scientific Q2 Loss After Financial Items SEK 30.5 Mln